Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 10, 2026LeukemiaOpen Access

A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha

View Full Paper
Ask AI
Bookmark
Share

Authors

RSRichard T. SilverHHHans Carl Hasselbalch

Discussion

Loading...

Member takes

Overview

Review highlights the benefits of early recombinant interferon alpha treatment in high and low-risk polycythemia vera patients, suggesting improved outcomes.

Key Points

  • To evaluate the effectiveness and safety of recombinant interferon alpha in treating polycythemia vera, emphasizing early intervention.
  • Reviewed single-arm studies on recombinant interferon alpha
  • Analyzed findings from the PROUD-CONTI study
  • Examined the Low-PV randomized trial results
  • Discussed European Medicines Agency and FDA approvals
  • Recombinant interferon alpha shows superiority over hydroxyurea in high-risk patients
  • Ropeginterferon alpha-2b approved for high-risk polycythemia vera
  • Low-risk patients benefit from ropeginterferon alpha compared to phlebotomy-only
  • Increased thrombotic risk observed even in low-risk patients

Cite This Study

Silver et al. (2026) studied this question.

synapsesocial.com/papers/69d895796c1944d70ce0669ahttps://doi.org/10.1038/s41375-026-02882-w
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical impact of mutated <scp>JAK2</scp> allele burden reduction in polycythemia vera and essential thrombocythemia2024 · 38 citations
  2. 2The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera2016 · 69 citations
  3. 3Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms—a Danish longitudinal study2024 · 41 citations
  4. 4JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders2008 · 173 citations
  5. 5Pegylated interferon: the who, why, and how2024 · 7 citations